HOME >> MEDICINE >> NEWS
First US tuberculosis vaccine trial in 60 years begins

A new vaccine, made with several proteins from the bacterium that causes tuberculosis (TB), will soon enter the first phase of human safety testing. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has supported research on the candidate vaccine from its earliest stages. The trial will be conducted in the United States by Seattle biotechnology company Corixa and GlaxoSmithKline Biologicals, a vaccine manufacturer headquartered in Belgium.

"This is the first recombinant tuberculosis vaccine to reach human trials in the United States," says NIAID Director Anthony S. Fauci, M.D. "Indeed, this is the first new TB vaccine to be tested in our country in more than 60 years. This candidate vaccine, as well as other novel products emerging from the TB research and development pipeline, offers hope for reducing the burden of a disease that claims approximately two million lives each year."

The vaccine combines two TB proteins known to stimulate strong immune responses in humans. The proteins were initially identified by screening blood taken from volunteers who never became ill with tuberculosis despite long-term infection with Mycobacterium tuberculosis bacteria. Using recombinant DNA technology, the TB proteins were fused and then combined with adjuvants, substances that further boost the immune system's response to the vaccine. NIAID grants awarded in the late 1990s supported research that uncovered the most effective adjuvant-protein combination.

NIAID's TB program officer, Christine Sizemore, Ph.D., notes, "This clinical trial is a wonderful example of advances made possible through sustained support and creative use of resources in NIAID's TB program." NIAID initially funded Corixa scientists, under the direction of Steven Reed, Ph.D., in their identification of the most promising TB proteins for use in a vaccine. Versions of the candidate vaccine were tested in animals through an NIAID
'"/>

Contact: Anne A. Oplinger
aoplinger@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
26-Jan-2004


Page: 1 2

Related medicine news :

1. First head-to-head study to compare lidoderm patch and Celebrex in treating pain
2. First UK cases of previously rare disease reported in gay men
3. First mouse model for multiple system atrophy points to new treatment targets for brain diseases
4. Mayo Clinic researchers create obedient virus; First step to use measles virus against cancer
5. First US kidney cancer vaccine trial underway at Columbia
6. First new treatment for alcoholism in ten years, now available Campral(R) (acamprosate calcium)
7. First blood test to diagnose paralyzing, blinding disease
8. First US SARS vaccine trial opens at NIH
9. First-ever safety study of medical cannabis use in Canada launched
10. First solid evidence that the study of music promotes intellectual development
11. First medical test on CD gets good results

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: First tuberculosis vaccine trial years begins

(Date:7/23/2014)... 2014 FCCI Insurance Group has been ... American Heart Association for helping employees eat better and ... Fit-Friendly Worksite in 2013, 2011, and 2010, and as ... employee health and wellness an important priority. We’re committed ... at the top of their game, and we are ...
(Date:7/23/2014)... 2014 Being overweight is no longer ... suggests that eating a diet high in processed and ... the risk for a host of diseases and weight ... in the bloodstream. , The body makes cholesterol, ... can cause thick, hard plaque to build up, clogging ...
(Date:7/23/2014)... 2014 Researchers in Turkey say a ... yellow pigment in the spice turmeric, and an immunosuppressor ... lab. To read the full story on Surviving ... University in Ankara, Turkey pretreated mesothelioma cells ... them to two platinum-based chemotherapy drugs with promising results. ...
(Date:7/23/2014)... (PRWEB) July 23, 2014 Daily Face & ... cheaper and safer alternative to Botox called Stem Cell ... is an anti-aging product used to help people smooth, tone, ... Serum can be used as a safe alternative to Botox, ... have any toxins or health risks as opposed to Botox. ...
(Date:7/23/2014)... Woodland Hills’ top cosmetic dentists ... bad breath that the condition is more than just a ... Jivraj and Dr. Mamaly Reshad of the Anacapa Dental Art ... some people may be overlooking an obvious sign of a ... an infection or chronic disease in the body,” Dr. Reshad ...
Breaking Medicine News(10 mins):Health News:FCCI Insurance Group Recognized as an American Heart Association Fit-Friendly Worksite 2Health News:FCCI Insurance Group Recognized as an American Heart Association Fit-Friendly Worksite 3Health News:Diet Doc’s Medical Weight Loss Programs Introduce Specialized Cholesterol Diet Plans that Deliver Fast Weight Loss and Reduce the Risk for Heart Attack and Stroke 2Health News:Diet Doc’s Medical Weight Loss Programs Introduce Specialized Cholesterol Diet Plans that Deliver Fast Weight Loss and Reduce the Risk for Heart Attack and Stroke 3Health News:New Research Finds Pretreatment of Mesothelioma Cells with These Two Compounds Boosts Chemotherapy Response, According to Surviving Mesothelioma 2Health News:New Research Finds Pretreatment of Mesothelioma Cells with These Two Compounds Boosts Chemotherapy Response, According to Surviving Mesothelioma 3Health News:Local Denver Skin Care Company Releases Safer Alternative to Botox 2Health News:Woodland Hills’ Top Cosmetic Dentists Offer 6 Tips on Causes of Bad Breath That Should Concern You 2Health News:Woodland Hills’ Top Cosmetic Dentists Offer 6 Tips on Causes of Bad Breath That Should Concern You 3Health News:Woodland Hills’ Top Cosmetic Dentists Offer 6 Tips on Causes of Bad Breath That Should Concern You 4Health News:Woodland Hills’ Top Cosmetic Dentists Offer 6 Tips on Causes of Bad Breath That Should Concern You 5
(Date:7/23/2014)... , July 23, 2014  Nearly 8,000 attendees will ... Cardinal Health,s annual Retail Business Conference (RBC), taking place ... Center. This year,s event encourages pharmacists to "Lead Change" ... communities and for their future. ... to network with their peers and learn new ways ...
(Date:7/23/2014)... Calif. , July 23, 2014  Cardica, Inc. (Nasdaq: ... financial results for its fiscal fourth quarter and year ended ... markets close. Cardica,s management will host a conference call at ... provide an update on the company,s business. Conference ... 7, 2014, at 4:30 p.m. Eastern Time via phone, please ...
(Date:7/23/2014)... a leader in R&D for new therapeutic solutions for the ... Growth Factor) has been designated as an orphan drug by ... The candidate drug, developed by the research of Dompe, has ... neurotrophic keratitis, a degenerative corneal disease that affects less than ... a cure. This is the second orphan drug designation by ...
Breaking Medicine Technology:Cardinal Health Encourages Independent Pharmacists to Lead Change at 24th Annual Retail Business Conference 2Cardinal Health Encourages Independent Pharmacists to Lead Change at 24th Annual Retail Business Conference 3Cardinal Health Encourages Independent Pharmacists to Lead Change at 24th Annual Retail Business Conference 4Cardinal Health Encourages Independent Pharmacists to Lead Change at 24th Annual Retail Business Conference 5Cardinal Health Encourages Independent Pharmacists to Lead Change at 24th Annual Retail Business Conference 6Cardica to Announce Fiscal 2014 Fourth Quarter and Full Year Financial Results on Thursday, August 7, 2014 2Dompe announces the Food and Drug Administration (FDA) has granted orphan drug designation to its rhNGF-based treatment for neurotrophic keratitis 2Dompe announces the Food and Drug Administration (FDA) has granted orphan drug designation to its rhNGF-based treatment for neurotrophic keratitis 3Dompe announces the Food and Drug Administration (FDA) has granted orphan drug designation to its rhNGF-based treatment for neurotrophic keratitis 4
Cached News: